[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100488439":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":17,"centralContacts":17,"locations":18,"responsibleParty":30,"collaborators":17,"id":32,"slug":33,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":36,"acronym":37,"eligibilityCriteria":38,"healthyVolunteers":34,"sex":39,"minAge":40,"maxAge":41,"enrollmentInfo":42,"targetDuration":17,"studyType":45,"phases":46,"briefSummary":48,"conditions":49,"keywords":17,"overallStatus":51,"whyStopped":17,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":60},{"fullName":5,"class":6},"University Hospital, Caen","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Aldosterone in HPLC-MS\u002FMS,","Aldosterone in HPLC-MS\u002FMS measurement",[12],"Other: Aldosterone in HPLC-MS\u002FMS",[14],{"type":6,"name":15,"description":15,"armGroupLabels":16,"otherNames":17},"Aldosterone in HPLC-MS\u002FMS",[9],null,[19],{"facility":20,"status":17,"city":21,"state":17,"zip":17,"country":22,"countryCode":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":17},"CAEN University Hospital","Caen","France","FR",{"type":25,"coordinates":26},"Point",[27,28],-0.35912,49.18585,{"lat":28,"lon":27},{"type":31,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR","100488439","determination-of-threshold-values-of-aldosterone-in-hplc-msms-of-renin-and-of-the-aldosterone--renin-ratio-for-the-diagnosis-of-primary-hyperaldosteronism-100488439",false,"NCT05640128","Determination of Threshold Values of Aldosterone in HPLC-MS\u002FMS, of Renin and of the Aldosterone \u002F Renin Ratio for the Diagnosis of Primary Hyperaldosteronism","DAPS","Inclusion Criteria:\n\n* Patients (18-75 years old) with moderate to severe hypertension, which justifies carrying out an etiological assessment in a hospital environment.\n* Assessment carried out in compliance with the standardized measurement conditions of the RAR defined by the SFE consensus,\n* Signature of a written consent by the patient\n\nExclusion Criteria:\n\n* Patient on antihypertensive treatment other than alpha-blockers, calcium channel blockers or centrally acting antihypertensive\n* Etiology of secondary hypertension other than PAH","ALL","18 Years","75 Years",{"count":43,"type":44},105,"ACTUAL","INTERVENTIONAL",[47],"NA","collaborative work within 2 hospitals at the CHU of Caen, at the CHRU of Lille, concerning the evaluation of the biological markers of primary hyperaldosteronism (PAH) with the dosage of aldosterone in LC -MS\u002FMS, which is performed in both centers, with two different techniques. The main objective is to define the range of Aldosterone concentrations in LC MS\u002FMS, of renin in an automated method, in populations of healthy volunteers, essential hypertensives, and hypertensives with primary hyperaldosteronism. , in order to establish a threshold for the screening of PAH by the RAR, and for the confirmation of PAH by a dynamic test with an Aldosterone threshold post salt load test.",[50],"Hyperaldosteronism; Primary","COMPLETED","2026-06-24",{"date":54,"type":44},"2026-06-26",{"date":56,"type":44},"2018-01-02",{"date":58,"type":44},"2025-06-27",{"name":5,"class":6},1]